SCHEMBL3626403

SCHEMBL3626403

CC(C)CCCC(C)C/C=C/C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 3/20 0.50
▸ LMNA P02545 3/20 0.43
▸ PTPN1 P18031 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ GABRR1 P24046 2/20 0.35
▸ GABRR2 P28476 2/20 0.35
▸ GABRR3 A8MPY1 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ APEX1 P27695 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GABRP O00591 2/20 0.33
▸ GABRD O14764 2/20 0.33
▸ GABRA1 P14867 2/20 0.33
▸ GABRB1 P18505 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3626405 1.00 BLM (0.50) BLMLMNAPTPN1CYP3A4TDP1
SCHEMBL23494092 0.88 BLM (0.38) BLMLMNACYP3A4TDP1ALDH1A1
SCHEMBL11835658 0.87 BLM (0.46) BLMLMNAPTPN1CYP3A4TDP1
SCHEMBL11835660 0.87 BLM (0.46) BLMLMNAPTPN1CYP3A4TDP1
SCHEMBL12811413 0.85 LMNA (0.38) BLMLMNACYP3A4TDP1ALDH1A1
SCHEMBL12811393 0.85 LMNA (0.38) BLMLMNACYP3A4TDP1ALDH1A1
SCHEMBL4199498 0.85 ACHE (0.47) BLMLMNAPTPN1CYP3A4TDP1
SCHEMBL3626573 0.85 ACHE (0.47) BLMLMNAPTPN1CYP3A4TDP1
SCHEMBL3414695 0.85 LMNA (0.38) BLMLMNACYP3A4TDP1ALDH1A1
SCHEMBL3414694 0.85 LMNA (0.38) BLMLMNACYP3A4TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7789934-B2 Combination of an N-alkyl- or N,N-dialkylpolyhydroxyalkanamide and a metal soap, an alkylenebisfatty amide, or an N-alkylalkanamide; improves both flowability and lubricity, regardless of a presence or absence of a complicated pretreatment step. KABUSHIKI KAISHA KOBE SEIKO SHO (JP) 2010-09-07 — — US disclosed
US-20070154340-A1 Lubricant for powder metallurgy, powdery mixture for powder metallurgy, and process for producing sinter KABUSHIKI KAISHA KOBE SEIKO SHO (JP) 2007-07-05 — — US disclosed
EP-1264853-B1 Polyol polymers, meso erythritol polymers and their aliphatic acid esters and aliphatic ethers RENGO CO LTD (JP) 2007-04-04 — — EP disclosed
US-6838544-B2 Polyol polymers, meso-erythritol polymers and their aliphatic acid esters and aliphatic ethers RENGO CO., LTD. (JP) 2005-01-04 — — US disclosed
US-20030017132-A1 Polyol polymers, meso-erythritol polymers and their aliphatic acid esters and aliphatic ethers RENGO CO., LTD. (JP) 2003-01-23 — — US disclosed
EP-1264853-A2 Polyol polymers, meso erythritol polymers and their aliphatic acid esters and aliphatic ethers Rengo Co., Ltd. (JP) 2002-12-11 — — EP disclosed
US-4915864-A CARBOXYLIC ACID OR SALTS THEREOF AS SOLUBILIZING AGENT WETTING AGENT FOR GLASS, FIBERS, METALS KAO CORPORATION (JP) 1990-04-10 — — US disclosed
EP-0296432-A2 Aqueous solution composition of strong alkali and nonionic surface active agent Kao Corporation (JP) 1988-12-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030017132-A1 Polyol polymers, meso-erythritol polymers and their aliphatic acid esters and aliphatic ethers PARG, EBPL, AGL BLM 1324/4885LMNA 761/4885PTPN1 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback